新的Se-化合物具有抗莱什曼尼,抗瘤和碳酸无水酶抑制性质
Cristina Morán-Serradilla1, Daniel Plano1, Andrea Angelli2
1Department of Pharmaceutical Sciences, University of Navarra, Pamplona, Spain.
Archiv der Pharmazie
|December 4, 2025
概括
新的化合物显示出对抗莱什曼病和癌症的前景. 衍生物3和6对寄生虫和癌细胞表现出强烈的活性,而化合物6抑制了关键的人类碳酸 anhydrase (hCA) 异型.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 莱什曼病和癌症是全球重要的健康挑战,需要新的治疗药物.
- 甲胺-相似物正在研究它们的潜在生物活性.
- 人类碳酸无水酶 (hCA) 与癌症进展有关,是潜在的治疗点.
研究的目的:
- 为了合成和评估类型的甲胺-类型的抗莱什曼和抗癌活动.
- 评估这些化合物对人类碳酸酶 (hCA) 异型的抑制作用.
- 为了确定活性化合物对癌细胞和正常细胞的选择性.
主要方法:
- 合成一个小的库的甲-胺-相似物.
- 在体外评估抗莱什曼尼菌对大莱什曼尼菌和婴儿莱什曼尼菌的活性.
- 在体外抗癌查对60个癌细胞系的小组 (国家癌症研究所的DTP).
- 在非恶性HaCaT细胞中进行细胞毒性评估.
- 对人类碳酸酶异型 (hCA I,II,IX和XII) 的抑制测定.
主要成果:
- 两种三甲氧基替代的氨酸衍生物 (化合物3和6) 显示出低微分子IC50值对Leishmania促性菌,具有比参考药物更好的选择性指数.
- 所有合成的化合物在广泛的癌症细胞系中表现出显著的抗瘤活性.
- 化合物6在低微分子范围内显示出与瘤相关的hCA XII和细胞质hCA II异型的强烈抑制.
结论:
- 基胺-类类似物代表了一类有前途的化合物,用于开发针对莱什曼病和癌症的新疗法.
- 化合物6是特别有前途的候选物,因为它对寄生虫,癌细胞和特定的hCA异型具有双重活性.
- 这些化合物对hCA异型的抑制需要进一步研究治疗应用.
更多相关视频
相关概念视频
Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
576
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
576
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
3.6K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the para...
3.6K


